We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
- Authors
Mondello, Patrizia; Steiner, Normann; Willenbacher, Wolfgang; Ferrero, Simone; Ghione, Paola; Marabese, Alessandra; Pitini, Vincenzo; Cuzzocrea, Salvatore; Mian, Michael
- Abstract
Background. Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especially for non-germinal center B-cell (non-GCB) DLBCL. However, routineclinical data are lacking, which is why we provide the results of the so-far largest relapsed/refractory (R/R) DLBCL real-life analysis. Methods. We retrospectively assessed 123 R/R DLBCL patients who received either 15 or 25 mg/day of lenalidomide from January 2006 to January 2015. Results. During a median follow-up period of 4.5 years, complete remission was achieved in 32% and a partial remission in 33% non-GCB patients compared with 0% and 3% in the GCB group (p < .001 and .001, respectively), with median response durations of 15 and 5 months, respectively (p < .001). Lenalidomide at 25 mg was superior to 15 mg in terms of response (complete remission 21% and partial remission 23% vs. 0% and 8%;p = .007 and .05) and median response duration (10 vs. 4 months; p = .03).Toxicity was limited and reversible. Median progression-free survival differed between non-GCB and GCB patients (37 vs. 30 months; p < .001) and between the two dosages (24 vs. 34 months; p = .002). However, overall survival was similar between the subgroups (38-42 months). Conclusion. We provide evidence that lenalidomide is a valid treatment option for R/R DLBCL, with limited and reversible toxicity, and is more efficient in non-GCB DLBCL and at higher doses.
- Subjects
ANTINEOPLASTIC agents; B cell lymphoma; CHI-squared test; IMMUNOHISTOCHEMISTRY; LONGITUDINAL method; DNA-binding proteins; DISEASE relapse; TREATMENT effectiveness; RETROSPECTIVE studies; DISEASE progression; DATA analysis software; KAPLAN-Meier estimator; LOG-rank test
- Publication
Oncologist, 2016, Vol 21, Issue 9, p1107
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2016-0103